Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis.
10.4046/trd.2013.75.6.256
- Author:
Seong Woo GO
1
;
Boo Kyeong KIM
;
Sung Hak LEE
;
Tae Jung KIM
;
Joo Yeon HUH
;
Jong Min LEE
;
Jick Hwan HAH
;
Dong Whi KIM
;
Min Jung CHO
;
Tae Wan KIM
;
Ji Young KANG
Author Information
1. Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. rkdwldud@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive;
Imatinib;
Lung Diseases, Interstitial
- MeSH:
Adrenal Cortex Hormones;
Follow-Up Studies;
Gastrointestinal Stromal Tumors;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive*;
Lung Diseases, Interstitial;
Mesylates*;
Pneumonia*;
Protein-Tyrosine Kinases;
Recurrence;
Imatinib Mesylate
- From:Tuberculosis and Respiratory Diseases
2013;75(6):256-259
- CountryRepublic of Korea
- Language:English
-
Abstract:
Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, which can frequently occur due to the underlying disease. The standard treatment for imatinib-induced pneumonitis is to discontinue the medication and optionally administer corticosteroids. However, there are a few cases of successful retrial with imatinib. We describe a case of successful rechallenge of imatinib in a patient with imatinib-induced interstitial pneumonitis and CML without a recurrence of the underlying disease after 3 months of follow-up.
